This focused issue on Surgery for Locally Advanced Pancreatic Cancer is edited by Dr. Elena Rangelova, MD, PhD, from Department of Upper GI Cancer, Division of HPB Surgery, Karolinska University Hospital, Stockholm, Sweden.
Dr. Rangelova is a pancreatic surgeon with special focus on locally advanced pancreatic cancer and dedicated to the development of national program for the treatment of LAPC. She is affiliated to Karolinska Institute with research interests on pancreatic cancer treatment and prevention, immunotherapy, and tumor biology.
Focused issue outline:
- Surgery for LAPC – a new old concept
- Resectable, borderline, and locally advanced pancreatic cancer – “the good, the bad, and the ugly” candidates for surgery?
- “Gold standard” for neoadjuvant therapy in LAPC
- Selecting the best candidates for resection among patients with LAPC
- Favorable tumor biology in locally advanced pancreatic cancer - more than just CA19-9
- Extent of venous resection during pancreatectomy – the balance between technically possible and biologically motivated
- How aggressive surgery is motivated for LAPC - arterial resection and total pancreatectomy?
- Surgery for locally advanced pancreatic cancer – is it only about the vessels?
- Can local ablative techniques replace surgery for locally advanced pancreatic cancer?
- Pathology reporting after neoadjuvant treatment needs a new standard. What is R0?
- How to select the most appropriate adjuvant therapy after resection for locally advanced pancreatic cancer